Suppr超能文献

一种从干血斑样本中进行 HIV 耐药性突变监测的经验证的内部检测方法。

A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens.

机构信息

National Sexually Transmitted and Blood-Borne Infections Laboratory, J.C. Wilt Infectious Diseases Research Centre at the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

National Sexually Transmitted and Blood-Borne Infections Laboratory, J.C. Wilt Infectious Diseases Research Centre at the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

出版信息

J Virol Methods. 2024 Jun;327:114939. doi: 10.1016/j.jviromet.2024.114939. Epub 2024 Apr 10.

Abstract

Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95% CI: 3200-10,700) copies/mL for the protease gene and 3600 (95% CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8% [95% CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7% [36.1-57.5] and 60.0% [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.

摘要

尽管抗逆转录病毒疗法(ART)的覆盖范围不断扩大,但与依从性和艾滋病毒耐药性(HIVDR)相关的挑战依然存在。在资源有限的环境中实施 HIVDR 监测的高昂成本仍然是一个持续存在的挑战。已证明干血斑(DBS)标本是替代血浆或血清进行 HIVDR 基因分型的可行方法,并且更适合资源较少的环境。需要能够以低成本从 DBS 标本中扩增 HIV-1 序列的经济实惠的 HIVDR 基因分型检测方法,特别是那些病毒载量较低的标本。在这里,我们介绍了一种能够可靠地从 DBS 标本中扩增 HIV-1 蛋白酶和部分逆转录酶基因的内部检测方法,该方法涵盖了世界卫生组织(WHO)2009 年监测耐药突变的完整清单。使用浓度为 10,000、5,000、1,000 和 500 拷贝/mL 的 HIV-1 全血对 DBS 标本进行了预混(每个浓度 30 个标本)。标本一式三份进行测试。采用两步法,包括 cDNA 合成和巢式 PCR。该检测方法的检测限计算为蛋白酶基因约为 5000(95%CI:3200-10,700)拷贝/mL,逆转录酶基因约为 3600(95%CI:2200-10,000)拷贝/mL。对于蛋白酶和逆转录酶,在 10,000 拷贝/mL 时,高病毒载量标本(97.8%[95%CI:92.2-99.7])的检测灵敏度最高,而随着病毒载量较低标本(蛋白酶为 46.7%[36.1-57.5],逆转录酶为 60.0%[49.1-70.2])的使用,检测性能逐渐下降。最终,该检测方法为资源有限的环境提供了一个很有前途的机会。未来的工作应包括在野外条件下进行验证,包括次优存储条件和使用指尖血制备 DBS,以准确反映实际采集情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验